RecruitingPhase 2NCT06991114

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

Sponsor

Artiva Biotherapeutics, Inc.

Enrollment

90 participants

Start Date

Jul 9, 2025

Study Type

INTERVENTIONAL

Conditions

Systemic Sclerosis (SSc)Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)

Summary

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing AlloNK, a type of natural killer (NK) cell therapy made from cord blood, in people with hard-to-treat autoimmune diseases including rheumatoid arthritis, Sjögren's disease, inflammatory muscle diseases (myopathies), and systemic sclerosis (scleroderma). **You may be eligible if...** - You have been diagnosed with one of the following: rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathy, or systemic sclerosis - Your disease remains active despite previous treatments - For rheumatoid arthritis: you have at least 6 swollen and 6 tender joints, and prior biologic treatment has failed - For Sjögren's disease: you have an active disease score above 6 and measurable saliva flow **You may NOT be eligible if...** - (Specific exclusion criteria were not listed in the available data) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAllogeneic NK Cells

AlloNK, dosed after a conditioning regimen, combined with Rituximab.

Locations(26)

Artiva Investigational Site Tuscaloosa

Tuscaloosa, Alabama, United States

Artiva Investigational Site Phoenix

Phoenix, Arizona, United States

Artiva Investigational Site Covina

Covina, California, United States

Artiva Investigational Site Los Alamitos

Los Alamitos, California, United States

Artiva Investigational Site Aventura

Aventura, Florida, United States

Artiva Investigational Site Jupiter

Jupiter, Florida, United States

Artiva Investigational Site Plantation

Plantation, Florida, United States

Artiva Investigational Site Willowbrook

Willowbrook, Illinois, United States

Artiva Investigational Site Iowa

Iowa City, Iowa, United States

Artiva Investigational Site Charlotte

Charlotte, North Carolina, United States

Artiva Investigational Site Charlotte

Charlotte, North Carolina, United States

Artiva Investigational Site Hixson

Hixson, Tennessee, United States

Artiva Investigational Site Arlington

Arlington, Texas, United States

Artiva Investigational Site Katy

Katy, Texas, United States

Artiva Investigational Site Mesquite

Mesquite, Texas, United States

Artiva Investigational Site Woodland

Woodland, Texas, United States

Artiva Investigational Site Sofia

Sofia, Bulgaria

Artiva Investigational Site Marseille

Marseille, France

Artiva Investigational Site Montpellier

Montpellier, France

Artiva Investigational Site Toulouse

Toulouse, France

Artiva Investigational Site Munchen

München, Germany

Artiva Investigational Site Brescia

Brescia, Italy

Artiva Investigational Site Vila Nova De Gaia

Vila Nova de Gaia, Portugal

Artiva Investigational Site Bucuresti

Bucharest, Romania

Artiva Investigational Site Bucharest

Bucharest, Romania

Artiva Investigational Site Sevila

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06991114

Related Trials

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT0630897818 locations

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT0665515574 locations

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT070879122 locations

MTS109 in Patients With Refractory Autoimmune Diseases

NCT075263501 location

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT074731546 locations